Diabetes Drug Revolution Gathers Pace, but Millions Still Struggle to Access Treatment

The article highlights the acceleration of innovation in weight loss drugs, noting that this is happening alongside ongoing gaps in access to basic, lifesaving diabetes care products like insulin in low- and middle-income countries. 

Specifically, it references the report's finding that many current projects by large, research-based pharmaceutical companies are being developed to improve blood sugar regulation and address metabolic conditions, including obesity. In contrast, research targeting Type 1 diabetes remains more limited. 

It also points out the report's finding that among 19 late-stage diabetes projects, only about half had an access plan, which could lead to delays in access for these projects upon approval. 

The article also explores Africa's unique challenges in expanding access to diabetes care products, noting the importance of building sustainable systems and securing financing to establish affordable prices and maintain reliable supplies.